Skip to content

    Stallion India Fluorochemicals Limited

    STALLION
    Chemicals·22 May 2025
    Management Summary

    Stallion India Fluorochemicals Ltd. delivered strong Q4 FY25 results, driven by robust demand and strategic execution, with significant QoQ growth in revenue, EBITDA, and PAT. The company is focused on forward integration and expansion into high-margin segments like semiconductor gases and HFOs, targeting a 30-35% CAGR over the next three years. While CapEx deployment saw initial delays due to redesigning and strong sales focus, new facilities are on track for completion by October 2025, setting the stage for future growth.

    Highlights

    5

    • Q4 FY25 total revenues of INR 153.16 crore, registering a robust 79.87% QoQ growth.

    • Q4 FY25 EBITDA rose 41.75% QoQ to INR 20.31 crores.

    • Q4 FY25 PAT came in at INR 13.27 crores, up 35.56% quarter-on-quarter.

    • Full year FY25 total revenues of INR 379.47 crores, with underlying PAT of INR 43.04 crores (excluding one-time provision).

    • Strategic investments in infrastructure and product development position for 30-35% CAGR over next three years, enhancing profitability by 3-4%.

    Concerns

    3

    • One-time provision of INR 10.71 crores made in H1 FY25 impacted reported full-year PAT.

    • Operational issues with banks caused delays in final payment of $33,800 for a contingent liability.

    • Capacity utilization figures in DRHP were described as 'paper working' and 'unrealistic' due to inability to run all facilities simultaneously.

    What Changed2

    vs Q2 FY26

    Guidance items15 → 5 (-10)Risks discussed7 → 5 (-2)
    Key financials

    Metrics

    8

    Periods

    3

    Q4 FY25

    3
    • Revenue
      ₹153.16 Cr
      QoQ+79.9%
    • EBITDA
      ₹20.31 Cr
      QoQ+41.8%
    • PAT
      ₹13.27 Cr
      QoQ+35.6%

    H1 FY25

    1
    • One-time Provision
      ₹10.71 Cr

    FY25

    4
    • Revenue
      ₹379.47 Cr
    • EBITDA
      ₹49.74 Cr
    • PAT
      ₹32.33 Cr
    • Underlying PAT
      ₹43.04 Cr

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    ₹0.69 crores

    IPO proceeds

    Liquidity

    Liquidity disclosed

    Operational issues with banks in closing payments for contingent liability due to document mismatches.

    Guidance & targets

    5
    CategoryTargetPriority
    Revenue
    Revenue CAGR
    30-35%
    		High
    Revenue
    New Products Revenue (Helium, NFC, Semiconductor)
    at least INR 100 crores
    		Medium
    Revenue
    HFO Products Revenue (Mambattu)
    another INR 100 crores
    		Medium
    Profitability
    Profitability Enhancement
    3-4%
    		High
    Capacity
    New Facilities Completion
    October 30th, 2025
    		High

    New Facilities Commercialization

    next quarter
    CurrentUnder redesigning/procurement
    TargetOn track for October 30th completion

    Why it matters

    Successful and timely commissioning of new facilities (Khalapur, Mambattu, Southern) is crucial for achieving the projected 30-35% CAGR and realizing new revenue streams.

    Overall, we will not lose time because the end what we have, 30th October is what we are looking at completion.

    How to verify

    guidance_and_targets[category='Capacity'][metric='New Facilities Completion']

    Risks & concerns

    5
    RiskSeverity

    Raw material price fluctuation and China dependency

    China controls 85% of global fluorochemicals raw material, leading to price fluctuations (over 100-300% historically). Managed by high inventory levels and strategic planning. — Both acknowledged

    medium

    Cyclicality of the fluorochemical industry

    Traditional fluorochemicals have cyclical upturns/downturns. Mitigated by diversification into sunrise industries like HFOs and semiconductor gases, which are expected to provide buffering. — Management acknowledged

    medium

    Operational issues with banks for contingent liability payments

    INR 0.00338 crores ($33,800) pending due to document mismatch, requiring RBI approval. Management states it is being resolved and will be paid. — Management acknowledged

    low

    High gestation period for new semiconductor/HFO business approvals

    Each product takes 2-3 years for approval, creating entry barriers. While helium sales will start instantly, full semiconductor product qualification takes time. — Management acknowledged

    medium

    Seasonal demand for refrigerants

    Demand varies significantly (10x difference between peak and off-peak). Capacity planning considers peak demand, with excess for export, making the business difficult to manage. — Management acknowledged

    medium

    Q&A highlights

    8

    “Basically, we are Stallion is across multi fields. It's not single. Like in the restaurant side of the business, you have companies like SRF, Navin, et cetera, who are competitors. These are the big names. Smaller names, there would be at least much, meaning much smaller than us and in the trade segment more than in the manufacturing segment. There would be at least another 10.”

    Provides an overview of the competitive landscape and highlights Stallion's diversified presence across multiple segments.

    asked by Sanket Sadh

    2 min read7 chapters

    Detailed Narrative

    01

    Q4 FY25 Performance and Full-Year Highlights

    Stallion India Fluorochemicals Ltd. reported strong Q4 FY25 results, with total revenues of INR 153.16 crore, marking a robust 79.87% quarter-on-quarter growth. EBITDA increased by 41.75% QoQ to INR 20.31 crores, and PAT grew 35.56% QoQ to INR 13.27 crores. For the full fiscal year 2025, the company achieved INR 379.47 crores in total revenues and an underlying PAT of INR 43.04 crores, excluding a one-time📎 provision of INR 10.71 crores made in H1.

    02

    Strategic Initiatives and Expansion Plans

    The company is actively pursuing forward integration, with successful project execution at Khalapur and Ghilot facilities, and groundwork for upcoming Mambattu and Specialty Gas Units. These expansions are designed to tap into high-margin segments such as semiconductor gases, HFOs, and liquid helium. Management projects a 30-35% CAGR over the next three years, with profitability expected to enhance by 3-4% through margin-accretive offerings.

    03

    CapEx Deployment and Capacity Utilization

    CapEx deployment post-IPO was initially delayed due to funds being received in late February, a strong sales focus in March, and necessary redesigning of facilities. The Mambattu facility, for example, was scaled up from a 5-tank to a 10-tank design. Management clarified that previous capacity utilization figures in the DRHP were 'paper working' and 'unrealistic,' stating current utilization is 'more than 50% everywhere.' All new facilities are targeted for completion by October 30th, 2025.

    04

    Contingent Liability Resolution

    A previously disclosed dispute with Chinese company Sunmai, which involved a notional loss of $7 million, is nearing full resolution. Out of the total settlement, only $33,800 (approximately INR 0.28 crores) remains pending. This delay is attributed to operational issues with banks related to document mismatches, which the company is actively resolving with RBI approval.

    05

    Market Dynamics and Product Strategy

    Stallion is diversifying its market focus from the oversaturated NCR Belt, where HFCs are predominantly used by OEMs, towards the West and South. The company is shifting towards higher-margin aftermarket sales (currently 70% of sales) and new products like HFOs and semiconductor gases, which are 100% OEM-driven. This strategy aims to buffer against industry cyclicality and capitalize on sunrise industries.

    06

    Raw Material Sourcing and Price Volatility

    The company acknowledges its reliance on China for 85% of global fluorochemical raw materials, which can lead to significant price fluctuations (historically over 100-300% increases). Stallion mitigates this risk through maintaining high inventory levels and strategic planning, including contingency plans for supply chain disruption🌐s.

    07

    HFO Business and Aftermarket Focus

    The HFO business, a key growth driver, is expected to add at least INR 100 crores in revenue from the Mambattu facility. Stallion holds a de facto exclusive position for HFO sales in India through its long-standing relationship with Honeywell. The company's strategy involves maintaining an OEM presence for new products while leveraging the higher margins and instant price mobility of the aftermarket for existing products.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.